We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Inmagene Biopharmaceuticals and Kissei Pharmaceutical Co., Ltd. announced today that they have entered into an exclusive license agreement for the development and commercialization of fostamatinib in mainland China, Hong Kong, S.A.R., China and Macau, S.A